Cohen & Chun; Ann Neurol. 2011 May;69(5):759-77.
In addition to its immune effects Fingolimod readily penetrates the CNS and may have direct effects on neural cells. This central mechanism of action distinguishes Fingolimod from other immunosuppressive drugs and may explain its positive effects on reducing the rate of brain atrophy.
"Whether Fingolimod is neuroprotective is not a moot point; it's currently being tested in primary progressive MS. We will know the answer in approximately 3 years."
COI: I sit on the steering committee responsible for the phase 4 development of Fingolimod and our group has received grant support to assess Fingolimod in our secondary progressive animal model of MS.